Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 16/20 | 0.51 |
| ▸ | FPR3 | P25089 | 1/20 | 0.47 |
| ▸ | FPR2 | P25090 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6131130 | 0.98 | CCR2 (0.51) | CCR2FPR3FPR2F2 | |
| SCHEMBL6131114 | 0.94 | CCR2 (0.52) | CCR2FPR3FPR2 | |
| SCHEMBL15844281 | 0.82 | CCR2 (0.47) | CCR2 | |
| SCHEMBL15844423 | 0.82 | CCR2 (0.47) | CCR2 | |
| SCHEMBL15844280 | 0.82 | CCR2 (0.47) | CCR2 | |
| SCHEMBL17048591 | 0.75 | TACR1 (0.49) | CCR2HRH3F2ALDH1A1 | |
| SCHEMBL5241932 | 0.73 | CCR2 (0.44) | CCR2FPR3FPR2 | |
| SCHEMBL8095243 | 0.72 | ERCC1 (0.55) | CCR2ALDH1A1 | |
| SCHEMBL17342646 | 0.72 | USP2 (0.56) | CCR2ALDH1A1 | |
| SCHEMBL5275905 | 0.71 | CCR2 (0.59) | CCR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558253-A4 | PIPERIDINYL-ALPHA-AMINOAMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20050250814-A1 | Piperidinyl-alpha-aminoamide modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2005-11-10 | — | — | US | disclosed |
| EP-1558253-A2 | PIPERIDINYL-ALPHA-AMINOAMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004042351-A2 | PIPERIDINYL-ALPHA-AMINOAMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250814-A1 | Piperidinyl-alpha-aminoamide modulators of chemokine receptor activity | CCR2, CCR1, CCRL2 | CCR2 1/4885FPR3 69/4885FPR2 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.